nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—sarcoma—peripheral nervous system neoplasm	0.198	1	CtDrD
Mitoxantrone—Topoisomerase Inhibitors—Topotecan—peripheral nervous system neoplasm	0.195	0.392	CiPCiCtD
Mitoxantrone—Topoisomerase Inhibitors—Etoposide—peripheral nervous system neoplasm	0.13	0.262	CiPCiCtD
Mitoxantrone—Topoisomerase Inhibitors—Epirubicin—peripheral nervous system neoplasm	0.0896	0.18	CiPCiCtD
Mitoxantrone—Topoisomerase Inhibitors—Doxorubicin—peripheral nervous system neoplasm	0.0829	0.167	CiPCiCtD
Mitoxantrone—ABCB1—peripheral nervous system neoplasm	0.0668	1	CbGaD
Mitoxantrone—TOP2A—Epirubicin—peripheral nervous system neoplasm	0.0172	0.102	CbGbCtD
Mitoxantrone—TOP2A—Etoposide—peripheral nervous system neoplasm	0.0134	0.0794	CbGbCtD
Mitoxantrone—ABCC1—Dactinomycin—peripheral nervous system neoplasm	0.0131	0.078	CbGbCtD
Mitoxantrone—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0127	0.0753	CbGbCtD
Mitoxantrone—ABCC1—Epirubicin—peripheral nervous system neoplasm	0.00952	0.0565	CbGbCtD
Mitoxantrone—TOP2A—Doxorubicin—peripheral nervous system neoplasm	0.00913	0.0542	CbGbCtD
Mitoxantrone—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.00879	0.0522	CbGbCtD
Mitoxantrone—ABCC1—Vincristine—peripheral nervous system neoplasm	0.00809	0.048	CbGbCtD
Mitoxantrone—ABCC1—Etoposide—peripheral nervous system neoplasm	0.00742	0.044	CbGbCtD
Mitoxantrone—CYP2E1—Dacarbazine—peripheral nervous system neoplasm	0.00723	0.0429	CbGbCtD
Mitoxantrone—CYP1B1—Doxorubicin—peripheral nervous system neoplasm	0.00712	0.0423	CbGbCtD
Mitoxantrone—ABCG2—Vincristine—peripheral nervous system neoplasm	0.00542	0.0321	CbGbCtD
Mitoxantrone—ABCC1—Doxorubicin—peripheral nervous system neoplasm	0.00506	0.03	CbGbCtD
Mitoxantrone—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.00505	0.03	CbGbCtD
Mitoxantrone—ABCG2—Etoposide—peripheral nervous system neoplasm	0.00496	0.0295	CbGbCtD
Mitoxantrone—ABCB1—Topotecan—peripheral nervous system neoplasm	0.00457	0.0272	CbGbCtD
Mitoxantrone—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.00457	0.0272	CbGbCtD
Mitoxantrone—CYP2E1—Etoposide—peripheral nervous system neoplasm	0.00354	0.021	CbGbCtD
Mitoxantrone—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.00338	0.0201	CbGbCtD
Mitoxantrone—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.00317	0.0188	CbGbCtD
Mitoxantrone—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.00274	0.0163	CbGbCtD
Mitoxantrone—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00255	0.0151	CbGbCtD
Mitoxantrone—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00195	0.0116	CbGbCtD
Mitoxantrone—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00182	0.0108	CbGbCtD
Mitoxantrone—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00179	0.0106	CbGbCtD
Mitoxantrone—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00122	0.00724	CbGbCtD
Mitoxantrone—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00117	0.00694	CbGbCtD
Mitoxantrone—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00107	0.00636	CbGbCtD
Mitoxantrone—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.000731	0.00434	CbGbCtD
Mitoxantrone—TOP2A—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000233	0.244	CbGdCrCtD
Mitoxantrone—TOP2A—Vindesine—Vincristine—peripheral nervous system neoplasm	0.000139	0.145	CbGdCrCtD
Mitoxantrone—PIM1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	0.000122	0.00859	CbGpPWpGaD
Mitoxantrone—BTK—TSLP Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.000121	0.00855	CbGpPWpGaD
Mitoxantrone—PIM1—GMCSF-mediated signaling events—HRAS—peripheral nervous system neoplasm	0.00012	0.00844	CbGpPWpGaD
Mitoxantrone—PIM1—C-MYB transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000117	0.00823	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-2-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.000111	0.00784	CbGpPWpGaD
Mitoxantrone—BTK—FAS (CD95) signaling pathway—CASP3—peripheral nervous system neoplasm	0.00011	0.00776	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—PPP3R1—peripheral nervous system neoplasm	0.000108	0.00758	CbGpPWpGaD
Mitoxantrone—SLC47A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000103	0.00722	CbGpPWpGaD
Mitoxantrone—BTK—Kit receptor signaling pathway—PTPN11—peripheral nervous system neoplasm	0.000101	0.00712	CbGpPWpGaD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—PTPN11—peripheral nervous system neoplasm	9.86e-05	0.00694	CbGpPWpGaD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	9.85e-05	0.00693	CbGpPWpGaD
Mitoxantrone—ABCC1—ABC-family proteins mediated transport—ABCB1—peripheral nervous system neoplasm	9.55e-05	0.00672	CbGpPWpGaD
Mitoxantrone—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	9.33e-05	0.00656	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—IFNB1—peripheral nervous system neoplasm	9.06e-05	0.00637	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	9.03e-05	0.00635	CbGpPWpGaD
Mitoxantrone—TOP2A—Vinorelbine—Vincristine—peripheral nervous system neoplasm	8.75e-05	0.0913	CbGdCrCtD
Mitoxantrone—TOP2A—Podofilox—Etoposide—peripheral nervous system neoplasm	8.74e-05	0.0913	CbGdCrCtD
Mitoxantrone—TOP2A—Teniposide—Etoposide—peripheral nervous system neoplasm	8.74e-05	0.0913	CbGdCrCtD
Mitoxantrone—PIM1—C-MYB transcription factor network—NRAS—peripheral nervous system neoplasm	8.51e-05	0.00599	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—MYC—peripheral nervous system neoplasm	8.33e-05	0.00586	CbGpPWpGaD
Mitoxantrone—PIM1—C-MYB transcription factor network—MYC—peripheral nervous system neoplasm	7.93e-05	0.00558	CbGpPWpGaD
Mitoxantrone—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	7.91e-05	0.00557	CbGpPWpGaD
Mitoxantrone—BTK—IL-5 Signaling Pathway—MYC—peripheral nervous system neoplasm	7.74e-05	0.00545	CbGpPWpGaD
Mitoxantrone—BTK—Class I PI3K signaling events—NRAS—peripheral nervous system neoplasm	7.56e-05	0.00532	CbGpPWpGaD
Mitoxantrone—BTK—EPO signaling pathway—HRAS—peripheral nervous system neoplasm	7.27e-05	0.00511	CbGpPWpGaD
Mitoxantrone—BTK—MyD88:Mal cascade initiated on plasma membrane—PTPN11—peripheral nervous system neoplasm	6.98e-05	0.00491	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—TP53—peripheral nervous system neoplasm	6.84e-05	0.00481	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—PTPN11—peripheral nervous system neoplasm	6.8e-05	0.00479	CbGpPWpGaD
Mitoxantrone—BTK—TSLP Signaling Pathway—MYC—peripheral nervous system neoplasm	6.8e-05	0.00479	CbGpPWpGaD
Mitoxantrone—SLC47A1—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	6.61e-05	0.00465	CbGpPWpGaD
Mitoxantrone—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—peripheral nervous system neoplasm	6.57e-05	0.00462	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	6.56e-05	0.00461	CbGpPWpGaD
Mitoxantrone—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—peripheral nervous system neoplasm	6.53e-05	0.00459	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	6.35e-05	0.00447	CbGpPWpGaD
Mitoxantrone—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	6.32e-05	0.00444	CbGpPWpGaD
Mitoxantrone—PIM1—C-MYB transcription factor network—HRAS—peripheral nervous system neoplasm	6.23e-05	0.00438	CbGpPWpGaD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—MYC—peripheral nervous system neoplasm	6.17e-05	0.00434	CbGpPWpGaD
Mitoxantrone—BTK—Activated TLR4 signalling—PTPN11—peripheral nervous system neoplasm	6.02e-05	0.00424	CbGpPWpGaD
Mitoxantrone—TOP2A—Vinblastine—Vincristine—peripheral nervous system neoplasm	6.02e-05	0.0628	CbGdCrCtD
Mitoxantrone—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—peripheral nervous system neoplasm	5.97e-05	0.0042	CbGpPWpGaD
Mitoxantrone—BTK—FAS (CD95) signaling pathway—AKT1—peripheral nervous system neoplasm	5.97e-05	0.0042	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—CD55—peripheral nervous system neoplasm	5.74e-05	0.00404	CbGpPWpGaD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—PTPN11—peripheral nervous system neoplasm	5.66e-05	0.00398	CbGpPWpGaD
Mitoxantrone—BTK—Class I PI3K signaling events—HRAS—peripheral nervous system neoplasm	5.53e-05	0.00389	CbGpPWpGaD
Mitoxantrone—BTK—IL-5 Signaling Pathway—AKT1—peripheral nervous system neoplasm	5.37e-05	0.00378	CbGpPWpGaD
Mitoxantrone—PIM1—Ectoderm Differentiation—MYC—peripheral nervous system neoplasm	5.33e-05	0.00375	CbGpPWpGaD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	5.21e-05	0.00367	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—ABCB1—peripheral nervous system neoplasm	5.18e-05	0.00364	CbGpPWpGaD
Mitoxantrone—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	5.1e-05	0.00359	CbGpPWpGaD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—TP53—peripheral nervous system neoplasm	5.07e-05	0.00357	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—PTPN11—peripheral nervous system neoplasm	5.04e-05	0.00355	CbGpPWpGaD
Mitoxantrone—BTK—TSLP Signaling Pathway—AKT1—peripheral nervous system neoplasm	4.72e-05	0.00332	CbGpPWpGaD
Mitoxantrone—TOP2A—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	4.56e-05	0.0476	CbGdCrCtD
Mitoxantrone—TOP2A—Idarubicin—Epirubicin—peripheral nervous system neoplasm	4.56e-05	0.0476	CbGdCrCtD
Mitoxantrone—TOP2A—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	4.56e-05	0.0476	CbGdCrCtD
Mitoxantrone—BTK—DAP12 signaling—PTPN11—peripheral nervous system neoplasm	4.47e-05	0.00314	CbGpPWpGaD
Mitoxantrone—BTK—Kit receptor signaling pathway—HRAS—peripheral nervous system neoplasm	4.45e-05	0.00313	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	4.43e-05	0.00311	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TH—peripheral nervous system neoplasm	4.35e-05	0.00306	CbGpPWpGaD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—HRAS—peripheral nervous system neoplasm	4.34e-05	0.00305	CbGpPWpGaD
Mitoxantrone—TOP2A—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	4.22e-05	0.044	CbGdCrCtD
Mitoxantrone—TOP2A—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	4.22e-05	0.044	CbGdCrCtD
Mitoxantrone—TOP2A—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	4.22e-05	0.044	CbGdCrCtD
Mitoxantrone—BTK—DAP12 interactions—PTPN11—peripheral nervous system neoplasm	4.2e-05	0.00296	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—PTPN11—peripheral nervous system neoplasm	4.2e-05	0.00296	CbGpPWpGaD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.19e-05	0.00295	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—PPP3R1—peripheral nervous system neoplasm	4.18e-05	0.00294	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CD34—peripheral nervous system neoplasm	4.17e-05	0.00294	CbGpPWpGaD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	4.11e-05	0.00289	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	4.03e-05	0.00284	CbGpPWpGaD
Mitoxantrone—BTK—BCR signaling pathway—HRAS—peripheral nervous system neoplasm	4.02e-05	0.00283	CbGpPWpGaD
Mitoxantrone—BTK—Kit receptor signaling pathway—AKT1—peripheral nervous system neoplasm	3.93e-05	0.00277	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—PTPN11—peripheral nervous system neoplasm	3.89e-05	0.00274	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	3.87e-05	0.00272	CbGpPWpGaD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—AKT1—peripheral nervous system neoplasm	3.83e-05	0.00269	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—MYC—peripheral nervous system neoplasm	3.81e-05	0.00268	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	3.77e-05	0.00265	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	3.69e-05	0.0026	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	3.64e-05	0.00256	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	3.63e-05	0.00256	CbGpPWpGaD
Mitoxantrone—BTK—BCR signaling pathway—AKT1—peripheral nervous system neoplasm	3.55e-05	0.0025	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	3.54e-05	0.00249	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—ERBB2—peripheral nervous system neoplasm	3.53e-05	0.00249	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	3.36e-05	0.00236	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CD55—peripheral nervous system neoplasm	3.34e-05	0.00235	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—ERBB2—peripheral nervous system neoplasm	3.32e-05	0.00234	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—ERBB2—peripheral nervous system neoplasm	3.32e-05	0.00234	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	3.23e-05	0.00228	CbGpPWpGaD
Mitoxantrone—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	3.08e-05	0.00216	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—ERBB2—peripheral nervous system neoplasm	3.08e-05	0.00216	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	3.01e-05	0.00212	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—HRAS—peripheral nervous system neoplasm	2.99e-05	0.00211	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	2.97e-05	0.00209	CbGpPWpGaD
Mitoxantrone—ABCG2—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	2.94e-05	0.00207	CbGpPWpGaD
Mitoxantrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	2.93e-05	0.00206	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—IFNB1—peripheral nervous system neoplasm	2.9e-05	0.00204	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CDKN2A—peripheral nervous system neoplasm	2.81e-05	0.00197	CbGpPWpGaD
Mitoxantrone—Headache—Tretinoin—peripheral nervous system neoplasm	2.75e-05	0.000511	CcSEcCtD
Mitoxantrone—Headache—Isotretinoin—peripheral nervous system neoplasm	2.75e-05	0.000511	CcSEcCtD
Mitoxantrone—Hypertension—Etoposide—peripheral nervous system neoplasm	2.74e-05	0.000511	CcSEcCtD
Mitoxantrone—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	2.74e-05	0.00051	CcSEcCtD
Mitoxantrone—Constipation—Vincristine—peripheral nervous system neoplasm	2.74e-05	0.00051	CcSEcCtD
Mitoxantrone—Pain—Vincristine—peripheral nervous system neoplasm	2.74e-05	0.00051	CcSEcCtD
Mitoxantrone—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	2.74e-05	0.00051	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	2.74e-05	0.00051	CcSEcCtD
Mitoxantrone—Rash—Melphalan—peripheral nervous system neoplasm	2.73e-05	0.000508	CcSEcCtD
Mitoxantrone—Dermatitis—Melphalan—peripheral nervous system neoplasm	2.73e-05	0.000508	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	2.72e-05	0.000506	CcSEcCtD
Mitoxantrone—Chest pain—Etoposide—peripheral nervous system neoplasm	2.71e-05	0.000504	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—MYC—peripheral nervous system neoplasm	2.7e-05	0.0019	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.7e-05	0.0019	CbGpPWpGaD
Mitoxantrone—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	2.7e-05	0.000503	CcSEcCtD
Mitoxantrone—Anorexia—Cisplatin—peripheral nervous system neoplasm	2.7e-05	0.000502	CcSEcCtD
Mitoxantrone—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	2.69e-05	0.000501	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—NRAS—peripheral nervous system neoplasm	2.69e-05	0.00189	CbGpPWpGaD
Mitoxantrone—Discomfort—Etoposide—peripheral nervous system neoplasm	2.67e-05	0.000498	CcSEcCtD
Mitoxantrone—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	2.66e-05	0.000496	CcSEcCtD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.65e-05	0.00187	CbGpPWpGaD
Mitoxantrone—Hypotension—Cisplatin—peripheral nervous system neoplasm	2.65e-05	0.000493	CcSEcCtD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	2.64e-05	0.00186	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	2.64e-05	0.000492	CcSEcCtD
Mitoxantrone—Urticaria—Alitretinoin—peripheral nervous system neoplasm	2.64e-05	0.000491	CcSEcCtD
Mitoxantrone—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	2.63e-05	0.000489	CcSEcCtD
Mitoxantrone—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	2.63e-05	0.000489	CcSEcCtD
Mitoxantrone—Nausea—Topotecan—peripheral nervous system neoplasm	2.62e-05	0.000489	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	2.62e-05	0.000487	CcSEcCtD
Mitoxantrone—Confusional state—Etoposide—peripheral nervous system neoplasm	2.61e-05	0.000487	CcSEcCtD
Mitoxantrone—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	2.61e-05	0.000486	CcSEcCtD
Mitoxantrone—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	2.61e-05	0.00183	CbGpPWpGaD
Mitoxantrone—Nausea—Tretinoin—peripheral nervous system neoplasm	2.6e-05	0.000485	CcSEcCtD
Mitoxantrone—Nausea—Isotretinoin—peripheral nervous system neoplasm	2.6e-05	0.000485	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	2.59e-05	0.000483	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	2.58e-05	0.00048	CcSEcCtD
Mitoxantrone—Infection—Etoposide—peripheral nervous system neoplasm	2.58e-05	0.00048	CcSEcCtD
Mitoxantrone—Asthenia—Dactinomycin—peripheral nervous system neoplasm	2.57e-05	0.000479	CcSEcCtD
Mitoxantrone—Nausea—Melphalan—peripheral nervous system neoplasm	2.57e-05	0.000479	CcSEcCtD
Mitoxantrone—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	2.56e-05	0.000477	CcSEcCtD
Mitoxantrone—Dehydration—Doxorubicin—peripheral nervous system neoplasm	2.55e-05	0.000474	CcSEcCtD
Mitoxantrone—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	2.54e-05	0.000473	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	2.54e-05	0.000473	CcSEcCtD
Mitoxantrone—BTK—Immune System—CD34—peripheral nervous system neoplasm	2.53e-05	0.00178	CbGpPWpGaD
Mitoxantrone—Tachycardia—Etoposide—peripheral nervous system neoplasm	2.53e-05	0.000471	CcSEcCtD
Mitoxantrone—Body temperature increased—Vincristine—peripheral nervous system neoplasm	2.53e-05	0.000471	CcSEcCtD
Mitoxantrone—Abdominal pain—Vincristine—peripheral nervous system neoplasm	2.53e-05	0.000471	CcSEcCtD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—NRAS—peripheral nervous system neoplasm	2.53e-05	0.00178	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—NRAS—peripheral nervous system neoplasm	2.53e-05	0.00178	CbGpPWpGaD
Mitoxantrone—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	2.52e-05	0.00047	CcSEcCtD
Mitoxantrone—Skin disorder—Etoposide—peripheral nervous system neoplasm	2.52e-05	0.000469	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	2.51e-05	0.000467	CcSEcCtD
Mitoxantrone—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	2.5e-05	0.000465	CcSEcCtD
Mitoxantrone—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	2.49e-05	0.000464	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.48e-05	0.00175	CbGpPWpGaD
Mitoxantrone—Anorexia—Etoposide—peripheral nervous system neoplasm	2.47e-05	0.00046	CcSEcCtD
Mitoxantrone—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	2.46e-05	0.000459	CcSEcCtD
Mitoxantrone—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	2.46e-05	0.000458	CcSEcCtD
Mitoxantrone—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	2.45e-05	0.000456	CcSEcCtD
Mitoxantrone—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	2.45e-05	0.000456	CcSEcCtD
Mitoxantrone—BTK—Immune System—PPP3R1—peripheral nervous system neoplasm	2.44e-05	0.00171	CbGpPWpGaD
Mitoxantrone—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	2.43e-05	0.000452	CcSEcCtD
Mitoxantrone—Hypotension—Etoposide—peripheral nervous system neoplasm	2.42e-05	0.000451	CcSEcCtD
Mitoxantrone—Pain—Cisplatin—peripheral nervous system neoplasm	2.42e-05	0.000451	CcSEcCtD
Mitoxantrone—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	2.41e-05	0.000449	CcSEcCtD
Mitoxantrone—CYP1B1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.4e-05	0.00169	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—AURKA—peripheral nervous system neoplasm	2.4e-05	0.00169	CbGpPWpGaD
Mitoxantrone—Neutropenia—Epirubicin—peripheral nervous system neoplasm	2.39e-05	0.000445	CcSEcCtD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	2.39e-05	0.00168	CbGpPWpGaD
Mitoxantrone—Asthenia—Alitretinoin—peripheral nervous system neoplasm	2.38e-05	0.000444	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	2.38e-05	0.000442	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	2.37e-05	0.00166	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	2.36e-05	0.000439	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—NRAS—peripheral nervous system neoplasm	2.34e-05	0.00165	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	2.33e-05	0.000434	CcSEcCtD
Mitoxantrone—Paraesthesia—Etoposide—peripheral nervous system neoplasm	2.33e-05	0.000434	CcSEcCtD
Mitoxantrone—Weight increased—Epirubicin—peripheral nervous system neoplasm	2.33e-05	0.000433	CcSEcCtD
Mitoxantrone—Weight decreased—Epirubicin—peripheral nervous system neoplasm	2.31e-05	0.000431	CcSEcCtD
Mitoxantrone—Dyspnoea—Etoposide—peripheral nervous system neoplasm	2.31e-05	0.000431	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	2.31e-05	0.000429	CcSEcCtD
Mitoxantrone—Somnolence—Etoposide—peripheral nervous system neoplasm	2.31e-05	0.000429	CcSEcCtD
Mitoxantrone—Asthenia—Vincristine—peripheral nervous system neoplasm	2.3e-05	0.000428	CcSEcCtD
Mitoxantrone—Pneumonia—Epirubicin—peripheral nervous system neoplasm	2.29e-05	0.000427	CcSEcCtD
Mitoxantrone—Drowsiness—Epirubicin—peripheral nervous system neoplasm	2.28e-05	0.000424	CcSEcCtD
Mitoxantrone—Vomiting—Dactinomycin—peripheral nervous system neoplasm	2.28e-05	0.000424	CcSEcCtD
Mitoxantrone—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	2.27e-05	0.000423	CcSEcCtD
Mitoxantrone—Rash—Dactinomycin—peripheral nervous system neoplasm	2.26e-05	0.000421	CcSEcCtD
Mitoxantrone—Decreased appetite—Etoposide—peripheral nervous system neoplasm	2.25e-05	0.00042	CcSEcCtD
Mitoxantrone—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	2.25e-05	0.000418	CcSEcCtD
Mitoxantrone—Renal failure—Epirubicin—peripheral nervous system neoplasm	2.24e-05	0.000417	CcSEcCtD
Mitoxantrone—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	2.24e-05	0.000417	CcSEcCtD
Mitoxantrone—Fatigue—Etoposide—peripheral nervous system neoplasm	2.24e-05	0.000416	CcSEcCtD
Mitoxantrone—Jaundice—Epirubicin—peripheral nervous system neoplasm	2.22e-05	0.000414	CcSEcCtD
Mitoxantrone—Stomatitis—Epirubicin—peripheral nervous system neoplasm	2.22e-05	0.000414	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—TP53—peripheral nervous system neoplasm	2.22e-05	0.00156	CbGpPWpGaD
Mitoxantrone—Pain—Etoposide—peripheral nervous system neoplasm	2.22e-05	0.000413	CcSEcCtD
Mitoxantrone—Constipation—Etoposide—peripheral nervous system neoplasm	2.22e-05	0.000413	CcSEcCtD
Mitoxantrone—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	2.22e-05	0.000413	CcSEcCtD
Mitoxantrone—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	2.22e-05	0.000413	CcSEcCtD
Mitoxantrone—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	2.21e-05	0.000412	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	2.2e-05	0.000409	CcSEcCtD
Mitoxantrone—Diarrhoea—Vincristine—peripheral nervous system neoplasm	2.19e-05	0.000408	CcSEcCtD
Mitoxantrone—Sweating—Epirubicin—peripheral nervous system neoplasm	2.19e-05	0.000407	CcSEcCtD
Mitoxantrone—ABCG2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.18e-05	0.00154	CbGpPWpGaD
Mitoxantrone—Haematuria—Epirubicin—peripheral nervous system neoplasm	2.17e-05	0.000405	CcSEcCtD
Mitoxantrone—BTK—Immune System—NCAM1—peripheral nervous system neoplasm	2.15e-05	0.00151	CbGpPWpGaD
Mitoxantrone—Weight increased—Doxorubicin—peripheral nervous system neoplasm	2.15e-05	0.000401	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—AURKA—peripheral nervous system neoplasm	2.14e-05	0.00151	CbGpPWpGaD
Mitoxantrone—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	2.14e-05	0.000398	CcSEcCtD
Mitoxantrone—Sinusitis—Epirubicin—peripheral nervous system neoplasm	2.14e-05	0.000398	CcSEcCtD
Mitoxantrone—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	2.14e-05	0.000398	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	2.13e-05	0.000397	CcSEcCtD
Mitoxantrone—Nausea—Dactinomycin—peripheral nervous system neoplasm	2.13e-05	0.000396	CcSEcCtD
Mitoxantrone—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	2.13e-05	0.000396	CcSEcCtD
Mitoxantrone—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	2.12e-05	0.000395	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	2.12e-05	0.000395	CcSEcCtD
Mitoxantrone—Vomiting—Alitretinoin—peripheral nervous system neoplasm	2.11e-05	0.000393	CcSEcCtD
Mitoxantrone—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	2.11e-05	0.000393	CcSEcCtD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	2.1e-05	0.00148	CbGpPWpGaD
Mitoxantrone—Rash—Alitretinoin—peripheral nervous system neoplasm	2.09e-05	0.00039	CcSEcCtD
Mitoxantrone—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	2.09e-05	0.00039	CcSEcCtD
Mitoxantrone—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	2.09e-05	0.000388	CcSEcCtD
Mitoxantrone—Bradycardia—Epirubicin—peripheral nervous system neoplasm	2.08e-05	0.000388	CcSEcCtD
Mitoxantrone—Headache—Alitretinoin—peripheral nervous system neoplasm	2.08e-05	0.000388	CcSEcCtD
Mitoxantrone—Renal failure—Doxorubicin—peripheral nervous system neoplasm	2.07e-05	0.000386	CcSEcCtD
Mitoxantrone—Urticaria—Etoposide—peripheral nervous system neoplasm	2.06e-05	0.000384	CcSEcCtD
Mitoxantrone—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	2.06e-05	0.000383	CcSEcCtD
Mitoxantrone—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	2.06e-05	0.000383	CcSEcCtD
Mitoxantrone—Jaundice—Doxorubicin—peripheral nervous system neoplasm	2.06e-05	0.000383	CcSEcCtD
Mitoxantrone—Rhinitis—Epirubicin—peripheral nervous system neoplasm	2.05e-05	0.000382	CcSEcCtD
Mitoxantrone—Body temperature increased—Etoposide—peripheral nervous system neoplasm	2.05e-05	0.000382	CcSEcCtD
Mitoxantrone—Abdominal pain—Etoposide—peripheral nervous system neoplasm	2.05e-05	0.000382	CcSEcCtD
Mitoxantrone—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	2.05e-05	0.000382	CcSEcCtD
Mitoxantrone—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	2.05e-05	0.000382	CcSEcCtD
Mitoxantrone—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	2.05e-05	0.000381	CcSEcCtD
Mitoxantrone—Hepatitis—Epirubicin—peripheral nervous system neoplasm	2.05e-05	0.000381	CcSEcCtD
Mitoxantrone—Vomiting—Vincristine—peripheral nervous system neoplasm	2.04e-05	0.000379	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	2.03e-05	0.00143	CbGpPWpGaD
Mitoxantrone—Asthenia—Cisplatin—peripheral nervous system neoplasm	2.03e-05	0.000378	CcSEcCtD
Mitoxantrone—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	2.03e-05	0.000378	CcSEcCtD
Mitoxantrone—Sweating—Doxorubicin—peripheral nervous system neoplasm	2.02e-05	0.000376	CcSEcCtD
Mitoxantrone—Rash—Vincristine—peripheral nervous system neoplasm	2.02e-05	0.000376	CcSEcCtD
Mitoxantrone—Dermatitis—Vincristine—peripheral nervous system neoplasm	2.02e-05	0.000376	CcSEcCtD
Mitoxantrone—Haematuria—Doxorubicin—peripheral nervous system neoplasm	2.01e-05	0.000374	CcSEcCtD
Mitoxantrone—Headache—Vincristine—peripheral nervous system neoplasm	2.01e-05	0.000373	CcSEcCtD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	1.98e-05	0.00139	CbGpPWpGaD
Mitoxantrone—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	1.98e-05	0.000368	CcSEcCtD
Mitoxantrone—Nausea—Alitretinoin—peripheral nervous system neoplasm	1.97e-05	0.000367	CcSEcCtD
Mitoxantrone—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	1.97e-05	0.000366	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—HRAS—peripheral nervous system neoplasm	1.97e-05	0.00138	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	1.94e-05	0.000361	CcSEcCtD
Mitoxantrone—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	1.93e-05	0.000359	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—CHEK2—peripheral nervous system neoplasm	1.92e-05	0.00135	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	1.91e-05	0.000356	CcSEcCtD
Mitoxantrone—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	1.9e-05	0.000354	CcSEcCtD
Mitoxantrone—Nausea—Vincristine—peripheral nervous system neoplasm	1.9e-05	0.000354	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—MYC—peripheral nervous system neoplasm	1.9e-05	0.00134	CbGpPWpGaD
Mitoxantrone—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	1.9e-05	0.000353	CcSEcCtD
Mitoxantrone—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	1.89e-05	0.000353	CcSEcCtD
Mitoxantrone—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	1.89e-05	0.000353	CcSEcCtD
Mitoxantrone—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	1.88e-05	0.00035	CcSEcCtD
Mitoxantrone—Asthenia—Etoposide—peripheral nervous system neoplasm	1.86e-05	0.000346	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—HRAS—peripheral nervous system neoplasm	1.85e-05	0.0013	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	1.85e-05	0.0013	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.85e-05	0.0013	CbGpPWpGaD
Mitoxantrone—Chills—Epirubicin—peripheral nervous system neoplasm	1.84e-05	0.000342	CcSEcCtD
Mitoxantrone—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	1.83e-05	0.00034	CcSEcCtD
Mitoxantrone—Alopecia—Epirubicin—peripheral nervous system neoplasm	1.81e-05	0.000337	CcSEcCtD
Mitoxantrone—Vomiting—Cisplatin—peripheral nervous system neoplasm	1.8e-05	0.000335	CcSEcCtD
Mitoxantrone—Rash—Cisplatin—peripheral nervous system neoplasm	1.78e-05	0.000332	CcSEcCtD
Mitoxantrone—Dermatitis—Cisplatin—peripheral nervous system neoplasm	1.78e-05	0.000332	CcSEcCtD
Mitoxantrone—Erythema—Epirubicin—peripheral nervous system neoplasm	1.78e-05	0.000332	CcSEcCtD
Mitoxantrone—Diarrhoea—Etoposide—peripheral nervous system neoplasm	1.77e-05	0.00033	CcSEcCtD
Mitoxantrone—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	1.74e-05	0.000325	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—AKT1—peripheral nervous system neoplasm	1.74e-05	0.00122	CbGpPWpGaD
Mitoxantrone—Back pain—Epirubicin—peripheral nervous system neoplasm	1.72e-05	0.000321	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—HRAS—peripheral nervous system neoplasm	1.71e-05	0.0012	CbGpPWpGaD
Mitoxantrone—Chills—Doxorubicin—peripheral nervous system neoplasm	1.7e-05	0.000316	CcSEcCtD
Mitoxantrone—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	1.69e-05	0.000315	CcSEcCtD
Mitoxantrone—BTK—Immune System—IFNB1—peripheral nervous system neoplasm	1.69e-05	0.00119	CbGpPWpGaD
Mitoxantrone—Nausea—Cisplatin—peripheral nervous system neoplasm	1.68e-05	0.000313	CcSEcCtD
Mitoxantrone—Vision blurred—Epirubicin—peripheral nervous system neoplasm	1.68e-05	0.000313	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.68e-05	0.00118	CbGpPWpGaD
Mitoxantrone—Alopecia—Doxorubicin—peripheral nervous system neoplasm	1.67e-05	0.000312	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	1.65e-05	0.000308	CcSEcCtD
Mitoxantrone—Vomiting—Etoposide—peripheral nervous system neoplasm	1.65e-05	0.000307	CcSEcCtD
Mitoxantrone—Erythema—Doxorubicin—peripheral nervous system neoplasm	1.65e-05	0.000307	CcSEcCtD
Mitoxantrone—Anaemia—Epirubicin—peripheral nervous system neoplasm	1.65e-05	0.000307	CcSEcCtD
Mitoxantrone—Rash—Etoposide—peripheral nervous system neoplasm	1.64e-05	0.000304	CcSEcCtD
Mitoxantrone—Dermatitis—Etoposide—peripheral nervous system neoplasm	1.63e-05	0.000304	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—PTPN11—peripheral nervous system neoplasm	1.63e-05	0.00115	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	1.63e-05	0.00115	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—AKT1—peripheral nervous system neoplasm	1.63e-05	0.00115	CbGpPWpGaD
Mitoxantrone—Headache—Etoposide—peripheral nervous system neoplasm	1.62e-05	0.000303	CcSEcCtD
Mitoxantrone—CYP1B1—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.62e-05	0.00114	CbGpPWpGaD
Mitoxantrone—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	1.61e-05	0.000301	CcSEcCtD
Mitoxantrone—Malaise—Epirubicin—peripheral nervous system neoplasm	1.61e-05	0.000299	CcSEcCtD
Mitoxantrone—Leukopenia—Epirubicin—peripheral nervous system neoplasm	1.59e-05	0.000297	CcSEcCtD
Mitoxantrone—Back pain—Doxorubicin—peripheral nervous system neoplasm	1.59e-05	0.000297	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	1.57e-05	0.0011	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.57e-05	0.0011	CbGpPWpGaD
Mitoxantrone—Cough—Epirubicin—peripheral nervous system neoplasm	1.55e-05	0.000289	CcSEcCtD
Mitoxantrone—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	1.55e-05	0.000289	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—BIRC5—peripheral nervous system neoplasm	1.55e-05	0.00109	CbGpPWpGaD
Mitoxantrone—Convulsion—Epirubicin—peripheral nervous system neoplasm	1.54e-05	0.000287	CcSEcCtD
Mitoxantrone—Nausea—Etoposide—peripheral nervous system neoplasm	1.54e-05	0.000287	CcSEcCtD
Mitoxantrone—Hypertension—Epirubicin—peripheral nervous system neoplasm	1.54e-05	0.000286	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	1.53e-05	0.000285	CcSEcCtD
Mitoxantrone—Anaemia—Doxorubicin—peripheral nervous system neoplasm	1.52e-05	0.000284	CcSEcCtD
Mitoxantrone—Chest pain—Epirubicin—peripheral nervous system neoplasm	1.52e-05	0.000282	CcSEcCtD
Mitoxantrone—Myalgia—Epirubicin—peripheral nervous system neoplasm	1.52e-05	0.000282	CcSEcCtD
Mitoxantrone—Arthralgia—Epirubicin—peripheral nervous system neoplasm	1.52e-05	0.000282	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—AKT1—peripheral nervous system neoplasm	1.51e-05	0.00106	CbGpPWpGaD
Mitoxantrone—Anxiety—Epirubicin—peripheral nervous system neoplasm	1.51e-05	0.000281	CcSEcCtD
Mitoxantrone—Discomfort—Epirubicin—peripheral nervous system neoplasm	1.5e-05	0.000279	CcSEcCtD
Mitoxantrone—Malaise—Doxorubicin—peripheral nervous system neoplasm	1.49e-05	0.000277	CcSEcCtD
Mitoxantrone—ABCG2—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.48e-05	0.00104	CbGpPWpGaD
Mitoxantrone—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	1.48e-05	0.000275	CcSEcCtD
Mitoxantrone—Confusional state—Epirubicin—peripheral nervous system neoplasm	1.47e-05	0.000273	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	1.46e-05	0.00103	CbGpPWpGaD
Mitoxantrone—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	1.45e-05	0.000271	CcSEcCtD
Mitoxantrone—Oedema—Epirubicin—peripheral nervous system neoplasm	1.45e-05	0.000271	CcSEcCtD
Mitoxantrone—ABCC1—Disease—GNS—peripheral nervous system neoplasm	1.45e-05	0.00102	CbGpPWpGaD
Mitoxantrone—Infection—Epirubicin—peripheral nervous system neoplasm	1.44e-05	0.000269	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.44e-05	0.00101	CbGpPWpGaD
Mitoxantrone—Cough—Doxorubicin—peripheral nervous system neoplasm	1.44e-05	0.000268	CcSEcCtD
Mitoxantrone—Shock—Epirubicin—peripheral nervous system neoplasm	1.43e-05	0.000266	CcSEcCtD
Mitoxantrone—Convulsion—Doxorubicin—peripheral nervous system neoplasm	1.43e-05	0.000266	CcSEcCtD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	1.42e-05	0.001	CbGpPWpGaD
Mitoxantrone—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	1.42e-05	0.000265	CcSEcCtD
Mitoxantrone—Hypertension—Doxorubicin—peripheral nervous system neoplasm	1.42e-05	0.000265	CcSEcCtD
Mitoxantrone—Tachycardia—Epirubicin—peripheral nervous system neoplasm	1.42e-05	0.000264	CcSEcCtD
Mitoxantrone—Skin disorder—Epirubicin—peripheral nervous system neoplasm	1.41e-05	0.000263	CcSEcCtD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	1.41e-05	0.000991	CbGpPWpGaD
Mitoxantrone—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	1.41e-05	0.000262	CcSEcCtD
Mitoxantrone—Myalgia—Doxorubicin—peripheral nervous system neoplasm	1.4e-05	0.000261	CcSEcCtD
Mitoxantrone—Chest pain—Doxorubicin—peripheral nervous system neoplasm	1.4e-05	0.000261	CcSEcCtD
Mitoxantrone—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	1.4e-05	0.000261	CcSEcCtD
Mitoxantrone—Anxiety—Doxorubicin—peripheral nervous system neoplasm	1.4e-05	0.00026	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.39e-05	0.000981	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—BIRC5—peripheral nervous system neoplasm	1.39e-05	0.000977	CbGpPWpGaD
Mitoxantrone—Discomfort—Doxorubicin—peripheral nervous system neoplasm	1.39e-05	0.000258	CcSEcCtD
Mitoxantrone—Anorexia—Epirubicin—peripheral nervous system neoplasm	1.39e-05	0.000258	CcSEcCtD
Mitoxantrone—Hypotension—Epirubicin—peripheral nervous system neoplasm	1.36e-05	0.000253	CcSEcCtD
Mitoxantrone—Confusional state—Doxorubicin—peripheral nervous system neoplasm	1.36e-05	0.000253	CcSEcCtD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.35e-05	0.000948	CbGpPWpGaD
Mitoxantrone—Oedema—Doxorubicin—peripheral nervous system neoplasm	1.35e-05	0.00025	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	1.35e-05	0.00025	CcSEcCtD
Mitoxantrone—Infection—Doxorubicin—peripheral nervous system neoplasm	1.34e-05	0.000249	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	1.33e-05	0.000935	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	1.32e-05	0.000247	CcSEcCtD
Mitoxantrone—Shock—Doxorubicin—peripheral nervous system neoplasm	1.32e-05	0.000246	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	1.32e-05	0.000245	CcSEcCtD
Mitoxantrone—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	1.31e-05	0.000244	CcSEcCtD
Mitoxantrone—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	1.31e-05	0.000243	CcSEcCtD
Mitoxantrone—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	1.31e-05	0.000243	CcSEcCtD
Mitoxantrone—BTK—Immune System—HGF—peripheral nervous system neoplasm	1.3e-05	0.000918	CbGpPWpGaD
Mitoxantrone—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	1.3e-05	0.000242	CcSEcCtD
Mitoxantrone—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	1.3e-05	0.000241	CcSEcCtD
Mitoxantrone—Somnolence—Epirubicin—peripheral nervous system neoplasm	1.29e-05	0.000241	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—ERBB2—peripheral nervous system neoplasm	1.29e-05	0.000908	CbGpPWpGaD
Mitoxantrone—Anorexia—Doxorubicin—peripheral nervous system neoplasm	1.28e-05	0.000239	CcSEcCtD
Mitoxantrone—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	1.28e-05	0.000238	CcSEcCtD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.26e-05	0.00089	CbGpPWpGaD
Mitoxantrone—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	1.26e-05	0.000235	CcSEcCtD
Mitoxantrone—Hypotension—Doxorubicin—peripheral nervous system neoplasm	1.26e-05	0.000234	CcSEcCtD
Mitoxantrone—Fatigue—Epirubicin—peripheral nervous system neoplasm	1.25e-05	0.000233	CcSEcCtD
Mitoxantrone—Constipation—Epirubicin—peripheral nervous system neoplasm	1.24e-05	0.000231	CcSEcCtD
Mitoxantrone—Pain—Epirubicin—peripheral nervous system neoplasm	1.24e-05	0.000231	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	1.24e-05	0.000872	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	1.23e-05	0.000866	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	1.23e-05	0.000228	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	1.22e-05	0.000856	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GNS—peripheral nervous system neoplasm	1.21e-05	0.000853	CbGpPWpGaD
Mitoxantrone—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	1.21e-05	0.000225	CcSEcCtD
Mitoxantrone—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	1.2e-05	0.000223	CcSEcCtD
Mitoxantrone—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	1.2e-05	0.000223	CcSEcCtD
Mitoxantrone—Somnolence—Doxorubicin—peripheral nervous system neoplasm	1.2e-05	0.000223	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	1.19e-05	0.000221	CcSEcCtD
Mitoxantrone—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	1.18e-05	0.00022	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.18e-05	0.000832	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.18e-05	0.000831	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GNS—peripheral nervous system neoplasm	1.17e-05	0.000825	CbGpPWpGaD
Mitoxantrone—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	1.17e-05	0.000218	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—NME1—peripheral nervous system neoplasm	1.16e-05	0.000818	CbGpPWpGaD
Mitoxantrone—Fatigue—Doxorubicin—peripheral nervous system neoplasm	1.16e-05	0.000216	CcSEcCtD
Mitoxantrone—Urticaria—Epirubicin—peripheral nervous system neoplasm	1.15e-05	0.000215	CcSEcCtD
Mitoxantrone—Pain—Doxorubicin—peripheral nervous system neoplasm	1.15e-05	0.000214	CcSEcCtD
Mitoxantrone—Constipation—Doxorubicin—peripheral nervous system neoplasm	1.15e-05	0.000214	CcSEcCtD
Mitoxantrone—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	1.15e-05	0.000214	CcSEcCtD
Mitoxantrone—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	1.15e-05	0.000214	CcSEcCtD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	1.14e-05	0.0008	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	1.14e-05	0.000799	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—NME1—peripheral nervous system neoplasm	1.12e-05	0.000791	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—COX2—peripheral nervous system neoplasm	1.12e-05	0.000787	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.11e-05	0.000783	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	1.11e-05	0.000206	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	1.1e-05	0.000205	CcSEcCtD
Mitoxantrone—CYP1B1—Metabolism—COX2—peripheral nervous system neoplasm	1.08e-05	0.000761	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	1.07e-05	0.000199	CcSEcCtD
Mitoxantrone—Urticaria—Doxorubicin—peripheral nervous system neoplasm	1.07e-05	0.000199	CcSEcCtD
Mitoxantrone—ABCG2—Metabolism—GNS—peripheral nervous system neoplasm	1.07e-05	0.000751	CbGpPWpGaD
Mitoxantrone—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	1.06e-05	0.000198	CcSEcCtD
Mitoxantrone—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	1.06e-05	0.000198	CcSEcCtD
Mitoxantrone—CYP2E1—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.06e-05	0.000745	CbGpPWpGaD
Mitoxantrone—Asthenia—Epirubicin—peripheral nervous system neoplasm	1.04e-05	0.000194	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDKN2A—peripheral nervous system neoplasm	1.03e-05	0.000724	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—NME1—peripheral nervous system neoplasm	1.02e-05	0.00072	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.02e-05	0.000716	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PPP3R1—peripheral nervous system neoplasm	1.01e-05	0.000712	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	9.99e-06	0.000703	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	9.98e-06	0.000702	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	9.95e-06	0.000185	CcSEcCtD
Mitoxantrone—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	9.91e-06	0.000185	CcSEcCtD
Mitoxantrone—ABCG2—Metabolism—COX2—peripheral nervous system neoplasm	9.85e-06	0.000693	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—NRAS—peripheral nervous system neoplasm	9.82e-06	0.000691	CbGpPWpGaD
Mitoxantrone—Asthenia—Doxorubicin—peripheral nervous system neoplasm	9.65e-06	0.00018	CcSEcCtD
Mitoxantrone—BTK—Immune System—PTPN11—peripheral nervous system neoplasm	9.51e-06	0.000669	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	9.43e-06	0.000664	CbGpPWpGaD
Mitoxantrone—Vomiting—Epirubicin—peripheral nervous system neoplasm	9.24e-06	0.000172	CcSEcCtD
Mitoxantrone—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	9.2e-06	0.000171	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—CDKN2A—peripheral nervous system neoplasm	9.2e-06	0.000647	CbGpPWpGaD
Mitoxantrone—Rash—Epirubicin—peripheral nervous system neoplasm	9.17e-06	0.000171	CcSEcCtD
Mitoxantrone—Dermatitis—Epirubicin—peripheral nervous system neoplasm	9.16e-06	0.000171	CcSEcCtD
Mitoxantrone—Headache—Epirubicin—peripheral nervous system neoplasm	9.11e-06	0.00017	CcSEcCtD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	8.95e-06	0.00063	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	8.78e-06	0.000618	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—ENO2—peripheral nervous system neoplasm	8.77e-06	0.000617	CbGpPWpGaD
Mitoxantrone—Nausea—Epirubicin—peripheral nervous system neoplasm	8.63e-06	0.000161	CcSEcCtD
Mitoxantrone—Vomiting—Doxorubicin—peripheral nervous system neoplasm	8.55e-06	0.000159	CcSEcCtD
Mitoxantrone—Rash—Doxorubicin—peripheral nervous system neoplasm	8.48e-06	0.000158	CcSEcCtD
Mitoxantrone—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	8.47e-06	0.000158	CcSEcCtD
Mitoxantrone—Headache—Doxorubicin—peripheral nervous system neoplasm	8.43e-06	0.000157	CcSEcCtD
Mitoxantrone—Nausea—Doxorubicin—peripheral nervous system neoplasm	7.99e-06	0.000149	CcSEcCtD
Mitoxantrone—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	7.98e-06	0.000561	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	7.7e-06	0.000542	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GNS—peripheral nervous system neoplasm	7.66e-06	0.000539	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—ERBB2—peripheral nervous system neoplasm	7.52e-06	0.000529	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—ENO2—peripheral nervous system neoplasm	7.35e-06	0.000517	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—NME1—peripheral nervous system neoplasm	7.34e-06	0.000517	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.28e-06	0.000512	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—HRAS—peripheral nervous system neoplasm	7.19e-06	0.000506	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—ENO2—peripheral nervous system neoplasm	7.11e-06	0.0005	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—SLC2A1—peripheral nervous system neoplasm	7.07e-06	0.000497	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—COX2—peripheral nervous system neoplasm	7.07e-06	0.000497	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	6.97e-06	0.000491	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	6.9e-06	0.000485	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	6.69e-06	0.000471	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	6.46e-06	0.000455	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—AKT1—peripheral nervous system neoplasm	6.34e-06	0.000446	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MYC—peripheral nervous system neoplasm	6.24e-06	0.000439	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—BCHE—peripheral nervous system neoplasm	6.21e-06	0.000437	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	6.09e-06	0.000429	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	6.08e-06	0.000427	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	6.01e-06	0.000423	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—BCHE—peripheral nervous system neoplasm	6e-06	0.000422	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.92e-06	0.000417	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—TH—peripheral nervous system neoplasm	5.84e-06	0.000411	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	5.77e-06	0.000406	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.73e-06	0.000403	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—NRAS—peripheral nervous system neoplasm	5.72e-06	0.000403	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—TH—peripheral nervous system neoplasm	5.64e-06	0.000397	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	5.53e-06	0.000389	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	5.46e-06	0.000384	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	5.32e-06	0.000375	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.21e-06	0.000367	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	5.14e-06	0.000361	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TP53—peripheral nervous system neoplasm	5.12e-06	0.00036	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.92e-06	0.000346	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.84e-06	0.00034	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GNAS—peripheral nervous system neoplasm	4.76e-06	0.000335	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	4.74e-06	0.000334	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—ABCB1—peripheral nervous system neoplasm	4.67e-06	0.000329	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—ENO2—peripheral nervous system neoplasm	4.64e-06	0.000327	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GNAS—peripheral nervous system neoplasm	4.61e-06	0.000324	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—ABCB1—peripheral nervous system neoplasm	4.52e-06	0.000318	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	4.19e-06	0.000295	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—HRAS—peripheral nervous system neoplasm	4.19e-06	0.000294	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	4.11e-06	0.000289	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PTPN11—peripheral nervous system neoplasm	3.95e-06	0.000278	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—BCHE—peripheral nervous system neoplasm	3.92e-06	0.000276	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	3.9e-06	0.000274	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.74e-06	0.000263	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—AKT1—peripheral nervous system neoplasm	3.7e-06	0.00026	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—TH—peripheral nervous system neoplasm	3.69e-06	0.000259	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	3.55e-06	0.00025	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	3.49e-06	0.000246	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	3.41e-06	0.00024	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	3.29e-06	0.000231	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	3.28e-06	0.000231	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—ERBB2—peripheral nervous system neoplasm	3.12e-06	0.00022	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GNAS—peripheral nervous system neoplasm	3.01e-06	0.000212	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—ABCB1—peripheral nervous system neoplasm	2.95e-06	0.000208	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	2.95e-06	0.000208	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.82e-06	0.000198	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	2.78e-06	0.000195	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—NRAS—peripheral nervous system neoplasm	2.38e-06	0.000167	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	2.27e-06	0.000159	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MYC—peripheral nervous system neoplasm	2.21e-06	0.000156	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	2.15e-06	0.000151	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.82e-06	0.000128	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HRAS—peripheral nervous system neoplasm	1.74e-06	0.000122	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.74e-06	0.000122	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.71e-06	0.00012	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—AKT1—peripheral nervous system neoplasm	1.54e-06	0.000108	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.4e-06	9.83e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.37e-06	9.64e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—AKT1—peripheral nervous system neoplasm	1.29e-06	9.05e-05	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—AKT1—peripheral nervous system neoplasm	1.24e-06	8.75e-05	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	1.13e-06	7.96e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—AKT1—peripheral nervous system neoplasm	8.12e-07	5.72e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	6.12e-07	4.3e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	3.77e-07	2.65e-05	CbGpPWpGaD
